Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials

Abstract Patients with multiple myeloma (MM) often use cardiovascular medications due to their increased risk of cardiovascular diseases. This study investigated the associations of baseline use of these drugs with survival and adverse events in MM patients initiating daratumumab, lenalidomide, or b...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Ahmad Y. Abuhelwa, Sara A Almansour, Humaid O. Al-Shamsi, Ziad Abuhelwa, Mohammad A. Y. Alqudah, Yasser Bustanji, Mohammad H Semreen, Karem H Alzoubi, Natansh D Modi, Ross A McKinnon, Michael J. Sorich, Ashley M Hopkins
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2026-02-01
סדרה:	Scientific Reports
נושאים:	Multiple myeloma Cardiovascular drugs Treatment outcomes Overall survival Progression-free survival Adverse events
גישה מקוונת:	https://doi.org/10.1038/s41598-026-37464-4
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!